To the Editor In their recent article in JAMA Oncology, Salazar et al¹ found that patients with non–small cell lung cancer treated with delayed chemotherapy, defined as chemotherapy administered after 56 days, had better outcomes, with hazard ratio of 0.664 (95% CI, 0.623-0.707; P < .001) compared with patients who received surgery alone. The authors listed multiple valid limitations to their study, including the retrospective nature of the National Cancer Database data that they used.

中文翻译：

---

肺癌手术后延迟辅助化疗和生存

致编辑在他们最近发表在JAMA Oncology上的文章中，Salazar 等人¹发现接受延迟化疗（定义为 56 天后进行化疗）治疗的非小细胞肺癌患者结局更好，风险比为 0.664（95% CI，0.623-0.707；P  < .001）与仅接受手术的患者相比。作者列出了他们研究的多个有效限制，包括他们使用的国家癌症数据库数据的回顾性。